Liminatus Pharma, Inc. (LIMN): Entry into a Material Definitive Agreement

Liminatus Pharma, Inc. (LIMN) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. On November 2, 2026, Liminatus Pharma, Inc. (the “Company”) entered into a subscription agreement (the “Subscription Agreement”) with a non-U.S. investor, pursuant to which such investor agreed to subscribe for, and the Compan

Event · Offering · priced
Instrument
common stock
Gross proceeds
$650,002.50
Shares
260,001 shares
Price per share
$2.50 per share
Use of proceeds
working capital and general corporate purposes

Facts are quoted from the filing text and checked against it.

Original reporting
Published Nov 3, 2026, 9:15 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 3, 2026, 9:18 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefCorporate actions
Primary signal
$LIMN
Neutral
high confidence
Mentioned
$LIMN
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$LIMNNeutralLow
01

Why it matters

The raise provides modest liquidity but introduces dilution; investors may watch the registration progress.

02

Market read

A micro‑cap equity raise with limited price impact; primarily relevant to LIMN shareholders and potential new investors.

03

What to watch

Potential strategic partnership with the non‑U.S. investor could bring future opportunities beyond the cash amount.

Relevance 6/10Novelty 6/10Timing: closing expected around November 20, 2026

Background

SEC Form 8‑K filing reports a private placement under Regulation D and S, with a commitment to register the shares for resale within 60 days.

Company-level read

Ticker impact

$LIMNNeutralHigh confidence
Context

Liminatus Pharma disclosed a private placement of 260,001 shares at $2.50 each, raising $650k for working capital.

Expected impact

likely slight pressure as the market prices in dilution from the new shares

Evidence & confidence

The 8‑K is the first public disclosure of the raise; the amount is small relative to market cap, so impact is limited.

Market effects

Minimal effect on the broader biotech/pharma sector; only a micro‑cap specific event.

No significant regional impact; the filing is U.S. focused.

Low global relevance; limited to investors in LIMN.

Counterpoint

If the capital is deployed effectively, the infusion could support growth and offset dilution concerns.

Key entities

  • Liminatus Pharma, Inc.

    Biopharmaceutical company issuing new shares.

  • Non‑U.S. investor

    Subscriber to the private placement.

Related articles

$LIMNMed

Liminatus Partners with Korean Firm for CAR

Liminatus Pharma partners with Synex Consulting to advance its CAR-T cell therapy in South Korea. The Ministry of Food and Drug Safety authorized a Phase 1/2a clinical study. Liminatus went public via a SPAC last year. Shares are down 8.2% to $4.73, with a $6.4M market cap.

$LIMNMed

Liminatus Pharma, Inc. (LIMN): Completion of Acquisition or Disposition of Assets

Liminatus Pharma, Inc. (LIMN) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. EX-2.1 2 tm2619730d1_ex2-1.htm EXHIBIT 2.1 Exhibit 2.1 AMENDED AND RESTATED MERGER AGREEMENT dated June 29, 2026 by and among InnocsAI LLC, Delaware limited liability company (the “ Company ”), NamChul Jung, as the Members’ Representative (the “ NamChul Jung ”), and Liminatus Pha

$LIMNMedAI 8/10

Liminatus Pharma Amends Merger Agreement With InnocsAI To Expand Oncology Pipeline

Liminatus Pharma (LIMN) amended its merger agreement with InnocsAI LLC to expand its oncology pipeline. The deal is now expected to close July 2, 2026, before stockholder approval. InnocsAI holders will receive Liminatus common stock and newly designated non-voting convertible preferred issued at $0.20/share, implying ~$320M value, plus CVRs on 20% of future net proceeds.